Lung Cancer
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib (ONC-003)
- Details
ClinicalTrials.gov ID:
NCT04486833
Diagnosis Type:
NA
USOR Number:
- Address
,
P: